DrugPatentWatch Database Preview

Patent: 9,963,507

« Back to Dashboard

Summary for Patent: 9,963,507

Title:	Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
Abstract:	Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies. Other characteristics of anti-B-cell antibodies that may be monitored include inducing phosphorylation of CD22, CD79a and CD79b; inducing translocation of CD22, CD79a and CD79b to lipid rafts; inducing caspase-dependent apoptosis; increasing pLyn, pERKs and pJNKs; decreasing constitutively-active p38; or inducing mitochondrial membrane depolarization, generation of reactive oxygen species, upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-xl, Mcl-1 and Bcl-2.
Inventor(s):	Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Hansen; Hans J. (Diamondhead, MS), Rossi; Edmund A. (Woodland Park, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	15/492,752
Patent Claims:	see list of patent claims

Details for Patent 9,963,507

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Merck	ELSPAR	asparaginase	VIAL	101063	001	1978-01-10		Immunomedics, Inc. (Morris Plains, NJ)	2031-12-05	RX		search

International Patent Family for US Patent 9,963,507

Country	Patent Number	Publication Date
Canada	2853138	Jun 13, 2013
Canada	2874541	Dec 05, 2013
China	104363919	Feb 18, 2015
European Patent Office	2788020	Apr 29, 2015